Evidence map›Paper›PMID 30258910›Full record

ReviewGenes & diseases2017

Ocular progenitor cells and current applications in regenerative medicines - Review.

K Gokuladhas, N Sivapriya, M Barath, Charles H NewComer

Open access · diamondAbstract readReview
In one paragraph

Review in Genes & diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

K GokuladhasWorld Stem Cell Clinic India LLP (ISO 9001:2015 Certified Clinic), #6, 9th Cross Street, Kapaleeshwar Nagar, Neelankarai, Chennai 600115, India.
N SivapriyaWorld Stem Cell Clinic India LLP (ISO 9001:2015 Certified Clinic), #6, 9th Cross Street, Kapaleeshwar Nagar, Neelankarai, Chennai 600115, India.
M BarathWorld Stem Cell Clinic India LLP (ISO 9001:2015 Certified Clinic), #6, 9th Cross Street, Kapaleeshwar Nagar, Neelankarai, Chennai 600115, India.
Charles H NewComerWorld Stem Cell Clinic India LLP (ISO 9001:2015 Certified Clinic), #6, 9th Cross Street, Kapaleeshwar Nagar, Neelankarai, Chennai 600115, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent emerging field of regenerative medicine is to present solutions for chronic diseases which cannot be sufficiently repaired by the body's own mechanisms. Stem cells are undifferentiated biological cells and have the potential to develop into many different cell types in the body during early life and growth. Self renewal and totipotency are the characteristic features of stem cells and it holds a promising result for treating various diseases like diabetic foot ulcer, heart diseases, lung diseases, Autism, Skin diseases, arthritis including eye disease. Failure of complete recovery of eye diseases and complications that follow conventional treatments have shifted search to a new form of regenerative medicine using Stem cells. The ocular progenitor cells are remarkable in stem cell biology and replenishing degenerated cells despite being present in low quantity and quiescence in our body has a high therapeutic value. In this paper we have review the applications on ocular progenitor stem cells in treatment of human eye diseases and address the strategies that have been exploited in an effort to regain visual function in the advance treatment of stem cells without any side effects and also present the significance in advance stem cell research.

Indexed as

Eye diseasesGlaucomaMacular degenerationOcular progenitor cellsRegenerative medicineStem cells

Identifiers

PMID30258910
PMCPMC6136601
OpenAlexW2587736671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.